Background: Increased cerebral signal intensity (SI) has been reported in patients undergoing MRI with gadolinium-based contrast agents (GBCAs). Published data on gadobenate dimeglumine have been somewhat contradictory. Purpose: To evaluate the relationship between dosage of gadobenate dimeglumine and SI change at MRI following multiple gadobenate dimeglumine administrations. Materials and Methods: In this retrospective study, patients referred for clinically indicated brain MRI from January 2006 through May 2016 were evaluated for inclusion. Eligible patients were between 18 and 90 years old at their baseline brain MRI and had never received a GBCA, had undergone three or more MRI examinations with gadobenate dimeglumine, and had the baseline scan and another brain MRI scan available for comparison. The primary group consisted of patients with four or fewer supratentorial lesions smaller than 3 cm who underwent axial T1-weighted MRI at 1.5 T. One patient had also undergone prior radiation therapy. The secondary group consisted of patients with a history of brain radiation therapy or craniotomy who underwent 1.5-T and 3-T same-plane T1-weighted MRI (in any order). The SI for up to eight brain MRI examinations per patient was measured, and relative SI changes from baseline to interval scans were calculated. A subgroup analysis was performed to assess the gadobenate dimeglumine washout since the last gadolinium exposure. All patients had normal renal and liver functions. Linear mixed regression analyses were performed for variables with P , .05. Results: In 43 patients (14 men, 29 women; median age, 49 years; age range, 25–73 years), the dentate nucleus (DN)–to–middle cerebral peduncle (MCP) SI ratio showed a mean increase of 6.7% 6 3.9 in the primary group and 4.0% 6 2.7 in the secondary group (both P , .001) following the administration of 134 mL 6 141 gadobenate dimeglumine over 55 months 6 35.2. The DN/ MCP SI ratio increased linearly with the amount of gadobenate dimeglumine, with a mean increase of 0.015% 6 0.004 per 1 mL of gadobenate dimeglumine (R2 = 0.3, P , .001). Conclusion: In patients receiving multiple doses of gadobenate dimeglumine, a linear relationship existed between gadobenate dimeglumine administrations and an increase in the dentate nucleus–to–middle cerebral peduncle signal intensity ratio at MRI.
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging